Stu Needleman, Chief Commercial Officer at Piramal Pharma Solutions, discusses the Biosecure Act and other big trends shaking up the industry

What’s going on in UK life sciences? How the government is offering support to the sector and investing in talent.

How small molecule-focused CDMOs can help companies navigate the impact of the Inflation Reduction Act.

How to mitigate the risks involved in highly potent APIs.

How can pharma improve patient access to medications? Christine Marsh of Boehringer Ingelheim offers her view.

Why we need to shift from reactive to proactive measures in tackling global health challenges.

How prefilled syringes, blow-fill-seal technology, and innovations in vials are transforming sterile manufacturing.

Regular injections to the eye are a reality for many patients. We must come up with better solutions for retinal degenerative diseases.

Choosing which medical congresses to target when launching your new medicine requires careful research and a sound strategy.

The pipeline of early-stage CRISPR therapeutics is huge, but advancing these innovations will require a multifaceted strategy.